Related Experiment Video
Updated: Feb 26, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities
Kate Roberts1, Vanessa Culleton1, Zarnie Lwin1,2,3
1Cancer Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Abstract:
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune-based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune-based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management.
Insights
Immune checkpoint inhibitors offer new cancer treatments but can cause unique immune-related side effects. This review details these toxicities and provides management guidelines for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immune checkpoint inhibitors represent a significant advancement in cancer therapy.
- These novel agents are associated with a distinct spectrum of immune-related adverse events.
- Effective management of these toxicities is crucial for patient safety and treatment success.
Purpose of the Study:
- To comprehensively review immune-related toxicities associated with immune checkpoint inhibitors.
- To provide evidence-based recommendations for the investigation of these adverse events.
- To outline guidelines for the specific management of immune-based toxicities.
Main Methods:
- Literature review of immune checkpoint inhibitor-related toxicities.
- Synthesis of current clinical guidelines and expert opinions.
- Analysis of reported adverse event profiles and management strategies.
Main Results:
- Detailed description of common and rare immune-related toxicities.
- Categorization of toxicities by organ system affected.
- Summary of diagnostic approaches and therapeutic interventions.
Conclusions:
- Early identification and prompt management of immune-related toxicities are essential.
- Adherence to established guidelines can optimize patient outcomes.
- Understanding and addressing these unique toxicities are critical for the safe and effective use of immune checkpoint inhibitors.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drug Toxicity: Dose-Dependent Reactions
Drug Toxicity: Overview

